Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA

Author(s): Yi Zhang, Longxiang Xie, Jianping Xie.

Journal Name: Letters in Drug Design & Discovery

Volume 13 , Issue 6 , 2016

Graphical Abstract:


Abstract:

With ever-increasing drug resistant clinical isolates, novel antibiotics with new targets are urgently needed. Tuberculosis, caused by Mycobacterium tuberculosis, showed formidable antibiotics resistance. InhA, the enoyl-acyl carrier protein (ACP) reductase involved in the type II fatty acid synthesis pathway (FASII) in Mycobacterium tuberculosis, represents an appealing target for the development of new anti-tuberculosis (TB) agents. Inhibitors against InhA might be ideal lead or antibiotics. The latest development of InhA inhibitors is summarized in this paper.

Keywords: Drug discovery, drug resistance, enoyl-ACP reductase, InhA, isoniazid, tuberculosis.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 6
Year: 2016
Page: [539 - 546]
Pages: 8
DOI: 10.2174/1570180812666151016205422
Price: $58

Article Metrics

PDF: 20
HTML: 2
EPUB: 1
PRC: 1